{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:05:13Z","timestamp":1769598313112,"version":"3.49.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T00:00:00Z","timestamp":1398124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients who present with palpable inguinal melanoma nodal metastasis have two surgical options: inguinal or ilioinguinal lymph node dissection. Indications for either operation remain controversial. This study examined survival and recurrence outcomes following ilioinguinal dissection for patients with palpable inguinal nodal metastasis, and assessed the incidence and preoperative predictors of pelvic nodal metastasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective clinicopathological analysis of consecutive surgical patients with stage III malignant melanoma. All patients underwent a standardized ilioinguinal dissection at a specialist tertiary oncology hospital over a 12-year period (1998\u20132010).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Some 38\u00b79 per cent of 113 patients had metastatic pelvic nodes. Over a median follow-up of 31 months, the 5-year overall survival rate was 28 per cent for patients with metastatic inguinal and pelvic nodes, and 51 per cent for those with inguinal nodal metastasis only (P = 0\u00b7002). The nodal basin control rate was 88\u00b75 per cent. Despite no evidence of pelvic node involvement on preoperative computed tomography (CT), six patients (5\u00b73 per cent) with a single metastatic inguinal lymph node had metastatic pelvic lymph nodes. Logistic regression analysis showed that the number of metastatic inguinal nodes (odds ratio 1\u00b756; P = 0\u00b7021) and suspicious CT findings (odds ratio 9\u00b789; P = 0\u00b7001) were both significantly associated with metastatic pelvic nodes. The specificity of CT was good (89\u00b72 per cent) in detecting metastatic pelvic nodes, but the sensitivity was limited (57\u00b79 per cent).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Metastatic pelvic nodes are common when palpable metastatic inguinal nodes are present. Long-term survival can be achieved following their resection by ilioinguinal dissection. As metastatic pelvic nodes cannot be diagnosed reliably by preoperative CT, patients presenting with palpable inguinal nodal metastasis should be considered for ilioinguinal dissection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/bjs.9502","type":"journal-article","created":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T10:14:50Z","timestamp":1398161690000},"page":"811-819","source":"Crossref","is-referenced-by-count":17,"title":["Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis"],"prefix":"10.1093","volume":"101","author":[{"given":"A R","family":"Glover","sequence":"first","affiliation":[{"name":"Kolling Institute of Medical Research, Royal North Shore Hospital and University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C P","family":"Allan","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M J","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Sarcoma and Melanoma Unit, Royal Marsden Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D C","family":"Strauss","sequence":"additional","affiliation":[{"name":"Sarcoma and Melanoma Unit, Royal Marsden Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Thomas","sequence":"additional","affiliation":[{"name":"Sarcoma and Melanoma Unit, Royal Marsden Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A J","family":"Hayes","sequence":"additional","affiliation":[{"name":"Sarcoma and Melanoma Unit, Royal Marsden Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,4,22]]},"reference":[{"key":"2021031210195563700_bjs9502-bib-0001","author":"National Cancer Intelligence Network","journal-title":"Mortality, Incidence and Gender\u00a0\u2013\u00a0Malignant Melanoma"},{"key":"2021031210195563700_bjs9502-bib-0002","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1365-2133.2004.06216.x","article-title":"The future incidence of cutaneous melanoma within the UK","volume":"151","author":"Diffey","year":"2004","journal-title":"Br J Dermatol"},{"key":"2021031210195563700_bjs9502-bib-0003","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"2021031210195563700_bjs9502-bib-0004","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00130404-200605000-00009","article-title":"Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes?","volume":"12","author":"Young","year":"2006","journal-title":"Cancer J"},{"key":"2021031210195563700_bjs9502-bib-0005","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/00000658-200206000-00017","article-title":"Long-term survival in 2505 patients with melanoma with regional lymph node metastasis","volume":"235","author":"White","year":"2002","journal-title":"Ann Surg"},{"key":"2021031210195563700_bjs9502-bib-0006","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1200\/JCO.2009.27.1627","article-title":"Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases","volume":"28","author":"Balch","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021031210195563700_bjs9502-bib-0007","volume-title":"Baseline Assessment of Sentinel Lymph Node Biopsy Practice Across England for Melanoma Patients, 2005\u20132009","author":"Ives","year":"2013"},{"key":"2021031210195563700_bjs9502-bib-0008","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2010.09883.x","article-title":"Revised UK guidelines for the management of cutaneous melanoma 2010","volume":"163","author":"Marsden","year":"2010","journal-title":"Br J Dermatol"},{"key":"2021031210195563700_bjs9502-bib-0009","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1445-2197.2008.04716.x","article-title":"Ilioinguinal lymph node dissection for palpable metastatic melanoma to the groin","volume":"78","author":"Allan","year":"2008","journal-title":"ANZ J Surg"},{"key":"2021031210195563700_bjs9502-bib-0010","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1245\/s10434-011-1741-0","article-title":"Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection","volume":"18","author":"van der Ploeg","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"2021031210195563700_bjs9502-bib-0011","volume-title":"AJCC Cancer Staging Manual","author":"Edge","year":"2010","edition":"7th"},{"key":"2021031210195563700_bjs9502-bib-0012","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00000658-198208000-00010","article-title":"Results of illoinguinal dissection for stage II melanoma","volume":"2","author":"Finck","year":"1982","journal-title":"Ann Surg"},{"key":"2021031210195563700_bjs9502-bib-0013","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/archsurg.1989.01410020032004","article-title":"Extent of lymph node dissection in melanoma of the trunk or lower extermity","volume":"124","author":"Coit","year":"1989","journal-title":"Arch Surg"},{"key":"2021031210195563700_bjs9502-bib-0014","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0002-9610(97)89622-5","article-title":"Positive deep nodes in the groin and survival in malignant melanoma","volume":"171","author":"Karakousis","year":"1996","journal-title":"Am J Surg"},{"key":"2021031210195563700_bjs9502-bib-0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10434-999-0255-5","article-title":"Positive iliac and obturator nodes in melanoma: survival and prognostic factors","volume":"6","author":"Strobbe","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"2021031210195563700_bjs9502-bib-0016","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10434-999-0263-5","article-title":"Does the extent of operation influence the prognosis in patients with melanoma metastatic to inguinal nodes?","volume":"6","author":"Mann","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"2021031210195563700_bjs9502-bib-0017","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1046\/j.1365-2168.2000.01439.x","article-title":"Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma","volume":"87","author":"Hughes","year":"2000","journal-title":"Br J Surg"},{"key":"2021031210195563700_bjs9502-bib-0018","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/028418601750071091","article-title":"Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin \u2013 an analysis of survival and local recurrence","volume":"40","author":"Kretschmer","year":"2001","journal-title":"Acta Oncol"},{"key":"2021031210195563700_bjs9502-bib-0019","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1245\/s10434-007-9512-7","article-title":"Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma","volume":"14","author":"Badgwell","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"2021031210195563700_bjs9502-bib-0020","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejso.2012.12.014","article-title":"The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases","volume":"39","author":"Zdzienicki","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"2021031210195563700_bjs9502-bib-0021","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1245\/s10434-011-1755-7","article-title":"Quality assurance parameters and predictors of outcome for ilioinguinal and inguinal dissection in a contemporary melanoma patient population","volume":"18","author":"Spillane","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"2021031210195563700_bjs9502-bib-0022","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021031210195563700_bjs9502-bib-0023","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/bjs.1800820819","article-title":"Ilioinguinal block dissection for malignant melanoma","volume":"82","author":"Sterne","year":"1995","journal-title":"Br J Surg"},{"key":"2021031210195563700_bjs9502-bib-0024","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/SLA.0b013e31824a5742","article-title":"Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma","volume":"255","author":"Bastiaannet","year":"2012","journal-title":"Ann Surg"},{"key":"2021031210195563700_bjs9502-bib-0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jnci\/djq455","article-title":"Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis","volume":"103","author":"Xing","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2021031210195563700_bjs9502-bib-0026","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1046\/j.1365-2168.1999.01316.x","article-title":"Combined inguinal and pelvic lymph node dissection for stage III melanoma","volume":"86","author":"Hughes","year":"1999","journal-title":"Br J Surg"},{"key":"2021031210195563700_bjs9502-bib-0027","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1245\/s10434-010-1203-0","article-title":"The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I)","volume":"17","author":"Faries","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"2021031210195563700_bjs9502-bib-0028","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1245\/s10434-009-0540-3","article-title":"False-negative sentinel node biopsy","volume":"16","author":"Nieweg","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"2021031210195563700_bjs9502-bib-0029","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamasurg.2013.1335","article-title":"Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result","volume":"148","author":"Jones","year":"2013","journal-title":"JAMA Surg"},{"key":"2021031210195563700_bjs9502-bib-0030","author":"Hoffmann-La","journal-title":"A Study of Vemurafenib Adjuvant Therapy in Patients with Resected Cutaneous BRAF Mutant Melanoma"},{"key":"2021031210195563700_bjs9502-bib-0031","author":"GlaxoSmithKline","journal-title":"A Study of the BRAF Inhibitor Dabrafenib in Combination with the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. (COMBI-AD)"},{"key":"2021031210195563700_bjs9502-bib-0032","author":"Australia and New Zealand Melanoma Trials Group","journal-title":"Proposed Trial 1\u00a0\u2013\u00a0ANZMTG 01.12 Inguinal or Ilio-inguinal Lymphadenectomy for Patients with Metastatic Melanoma to Groin Lymph Nodes and No Evidence of Pelvic Disease on PET\/CT Scan\u00a0\u2013\u00a0a Randomised Phase III Trial (EAGLE FM)"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.9502","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/101\/7\/811\/36581493\/bjs9502.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/101\/7\/811\/36581493\/bjs9502.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T14:11:23Z","timestamp":1621519883000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/101\/7\/811-819\/6137980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,22]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,4,22]]},"published-print":{"date-parts":[[2014,5,12]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.9502","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,6]]},"published":{"date-parts":[[2014,4,22]]}}}